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Abstract 
Background: Septic shock is a life-threatening condition that challenges immune 
cells to reprogram their mitochondrial metabolism towards to increase ATP synthesis 
for building an appropriate immunity. This could print metabolic signatures in mito-
chondria whose association with disease progression and clinical outcomes remain 
elusive.
Method: This is a single-center prospective cohort study performed in the ICU of one 
tertiary referral hospital in Brazil. Between November 2017 and July 2018, 90 con-
secutive patients, aged 18 years or older, admitted to the ICU with septic shock were 
enrolled. Seventy-five patients had Simplified Acute Physiology Score (SAPS 3) assessed 
at admission, and Sequential Organ Failure Assessment (SOFA) assessed on the first 
(D1) and third (D3) days after admission. Mitochondrial respiration linked to complexes 
I, II, V, and biochemical coupling efficiency (BCE) were assessed at D1 and D3 and Δ 
(D3–D1) in isolated lymphocytes. Clinical and mitochondrial endpoints were used to 
dichotomize the survival and death outcomes. Our primary outcome was 6-month 
mortality, and secondary outcomes were ICU and hospital ward mortality.
Results: The mean SAPS 3 and SOFA scores at septic shock diagnosis were 75.8 
(± 12.9) and 8 (± 3) points, respectively. The cumulative ICU, hospital ward, and 
6-month mortality were 32 (45%), 43 (57%), and 50 (66%), respectively. At the ICU, non-
surviving patients presented elevated arterial lactate (2.8 mmol/L, IQR, 2–4), C-reactive 
protein (220 mg/L, IQR, 119–284), and capillary refill time (5.5 s, IQR, 3–8). Respiratory 
rates linked to CII at D1 and D3, and ΔCII were decreased in non-surviving patients. 
Also, the BCE at D1 and D3 and the ΔBCE discriminated patients who would evolve to 
death in the ICU, hospital ward, and 6 months after admission. After adjusting for pos-
sible confounders, the ΔBCE value but not SOFA scores was independently associated 
with 6-month mortality (RR 0.38, CI 95% 0.18–0.78; P = 0.009). At a cut-off of − 0.002, 
ΔBCE displayed 100% sensitivity and 73% specificity for predicting 6-month mortality
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Conclusions: The ΔBCE signature in lymphocytes provided an earlier recognition of 
septic shock patients in the ICU at risk of long-term deterioration of health status.
Keywords: Septic shock, Lymphocytes, Mitochondrial signatures, Mortality, Prognostic 
biomarker
Introduction
Sepsis is a disorder that develops as organ disfunction, and remains one of the leading 
causes of death globally. Although it may benefit from early diagnostic and prompt treat-
ments to minimize mortality, the availability of diagnostic tools to better predict out-
comes and support early clinical decisions are still limited. Septic shock, the most severe 
end of the spectrum of sepsis, represents a life-threatening condition, which requires 
vasopressor therapy to treat profound circulatory and metabolic abnormalities [1, 2]. 
Indeed, during septic shock the oxidative metabolism in several tissues may be limited 
by the oxygen saturation, delivery, and utilization by mitochondria. Therefore, an early 
antibiotic therapy, fluid resuscitation and vasopressor drugs alone may not overcome the 
respiratory deficits at the cellular level. This highlights that inherent or acquired mito-
chondrial defects associated with septic shock may hinder oxygen consumption coupled 
with ATP synthesis (OXPHOS), independent of standard therapeutic interventions, 
thereby contributing to mechanisms underlying organ failure and, eventually, to patient’s 
death [3–5].
Current advances in the understanding of the physiopathology of sepsis have incor-
porated the concept of an existing crosstalk between immune cells metabolism and 
immunity [5–9]. The inflammatory course of septic shock challenges the immune cells 
to enhance their production of antibodies and signaling molecules over time, which 
relies on an increased energy consumption supported by the mitochondrial metabolic 
machinery [7, 10]. Based on this, mitochondria of lymphocytes are constantly repro-
gramming their metabolism, with the increased activity of oxidative complexes reflect-
ing their higher requirements for ATP synthesis by working at high respiratory rates or 
the downregulation of oxidative complexes reflecting decreased ATP demands or mito-
chondrial metabolic exhaustion [9]. These unique features suggest that mitochondria 
might print metabolic signatures in immune cells of septic shock patients whose clinical 
significance as a biomarker remains elusive [4, 5, 11–14]. Remarkably, the rates of oxy-
gen consumption associated with individual mitochondrial complexes can be profiled 
in lymphocytes by respirometry protocols allowing to derive a composite of metabolic 
signatures that may serve as candidate biomarkers of clinical outcomes. Particularly, the 
BCE is a parameter which scores how efficiently the mitochondrial machinery are syn-
chronized towards ATP-synthesis [15, 16].
Early studies have analyzed OXPHOS metabolism in sepsis, with controversial results 
mainly regarding the capability of metabolic endpoints to predict organ failure and mor-
tality [4, 5, 11–14, 17]. In general, they focused on sepsis and did not include a large 
number of patients with septic shock, which reduced the power of clinical associations 
between organ failure, mortality, the effectiveness of therapies and specific mitochon-
drial respiratory states. Also, few studies conducted a strategy of two sequential assess-
ments in the ICU setting and following its impact on the short-, mid- and long-term 
prognosis.
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Therefore, there are still gaps to fill regarding mitochondrial metabolic signatures 
in immune cells as feasible biomarkers for septic shock patients admitted to the ICU. 
Accordingly, we aimed to investigate mitochondrial bioenergetic signatures in lympho-
cytes associated with mortality for septic shock.
Material and methods
Participants and study design
This is a prospective cohort study designed to evaluate the mitochondrial metabolism 
of circulating lymphocytes in septic shock patients admitted to four different ICUs from 
one tertiary university public hospital in Brazil. This study was approved by the local 
ethics committee (Plataforma Brazil number 66240017.0.0000.5530). We prospectively 
enrolled 90 adult patients (> 18 years old, 45% were women) admitted to the ICU due 
to septic shock between November 2017 and July 2018 as indicated in Fig. 1. Patients 
were excluded if they presented with a known mitochondrial disease, pregnancy, refusal 
of the patient or the next of kin to sign the informed consent, patients with imminent 
death, and patients with withholding or withdrawing treatments. Septic shock was 
defined as the presence of persistent hypotension with the requirement of vasopres-
sor therapy to maintain a mean arterial pressure of 65 mmHg or greater according to 
Sepsis 2001 definition [18]. The following demographic and clinical characteristics were 
prospectively recorded: gender, age, primary site of infection, community-acquired or 
hospital-acquired infection, comorbidities, noradrenaline maximum dose, lactate level, 
Fig. 1 Flow diagram. Ninety patients were initially engaged in the study protocol, but 15 progressed to 
death on day 1 of admission. Seventy-five septic shock patients completed the study
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urine output,  PaO2:FiO2 ratio, serum creatinine, total bilirubin, platelets, international 
normalized rate (INR), Glasgow Coma Scale, capillary refill time, central venous satura-
tion  (SvO2), length of ICU and length of hospital stay. Also, Simplified Acute Physiol-
ogy Score (SAPS 3) and the Sequential Organ Failure Assessment (SOFA) score were 
assessed [19, 20]. The SOFA score was used as a tool for defining both, the clinical condi-
tion of the individual patient and the response to therapies [21], as well as delta SOFA 
as an indicator of resolved or unresolved clinical condition [22]. This score is a gold 
standard for predicting hospital mortality, providing detailed information regarding the 
number and severity of organic failure in septic patients [23]. The management of septic 
shock in these patients was carried out as recommended by Surviving Sepsis Campaign 
[24] guidelines, especially with regard to early antibiotic therapy, culture collection, fluid 
replacement and preferential use of norepinephrine as first-line vasopressor drug.
Clinical and laboratory endpoints, including mitochondrial respirometry in permea-
bilized lymphocytes (digitonin 0.005% w/v), were evaluated at two timepoints: the first 
day of ICU admission (D1) and three days after admission (D3). The pairwise variations 
between D1 and D3 (Δ) were used to estimate the improvement or the worsening of the 
clinical, laboratory and mitochondrial endpoints. SOFA and mitochondrial endpoints 
were used to dichotomize the survival and death outcomes. The primary outcome was 
6-month mortality for septic shock, and the secondary outcomes were ICU and hospital 
mortality.
Isolation of lymphocytes and mitochondrial respirometry
Six milliliters of blood were sampled in EDTA tubes at D1 and D3. Lymphocytes were 
isolated as described by Pecina et al. [25]. We assayed mitochondrial respiration in per-
meabilized lymphocytes isolated at D1 and D3. The cells counting showed 98% of the 
lymphocytes in the fraction.
The high-resolution respirometry measurements were performed within 3 h of blood 
sampling using oxygraphy (Oxygraph-2  k; Oroboros Instruments, Innsbruck, Austria) 
at 37  °C. Oxygen concentration (micromolar) and oxygen flux (expressed in pmol  O2.
s−1.mg of protein) were recorded with DatLab software 6.0. The basal oxygen consump-
tion (oxygen flow per volume or per mass) was established without metabolic substrates. 
Subsequently, stepwise additions of pyruvate, malate and glutamate (10, 10 and 20 mM, 
respectively), followed by 2.5 mM ADP, 10 mM succinate, a second 2.5 mM ADP, and 
finally sodium azide plus antimycin A were performed. This protocol assesses the res-
piration linked to Complex I (CI), Complex II (CII) and maximal oxygen flow rate con-
sumption coupled to ATP production (P), and nonmitochondrial oxygen consumption 
[26].
The BCE (also known as ≈ P control factor) was measured to estimate the mitochon-
drial oxygen flow coupled to ATP production. The BCE is calculated by the P–L/P fluxes; 
(J ≈  P = (P −  L)/P), as described previously [15, 16]. A representative image display-
ing the sequential addition of the substrates to the permeabilized lymphocytes, and the 
derived respiratory parameters obtained from a control subject, are shown in Additional 
file  1: Figure S1. The researchers involved in the mitochondrial analysis were blinded 
to the clinical outcomes, and the researchers involved in the clinical data collection 
were blinded to the mitochondrial outcomes. All chemicals used for high-resolution 
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respirometry analysis were analytical grade, purchased from Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MO, USA).
Statistical analysis
Descriptive statistics included frequencies and percentages for the categorical variables 
and means, and standard deviation, confidence intervals, medians, and interquartile 
ranges for continuous variables. Student’s t-test or the Mann–Whitney U test were used 
to compare continuous variables according to normality, assessed by Shapiro–Wilk test. 
Chi-square test or Fisher’s exact test were used to analyze categorical variables. Associa-
tion between two continuous variables was measured with Spearman correlation coef-
ficient. To access the impact of BCE improvement at D3 (ΔBCE > 0) on the outcomes, 
Poisson regression was performed with 6-month mortality as the dependent variable, 
and hematological neoplasia, chronic kidney disease, lactate at septic shock diagnosis, 
SOFA improvement at D3 (ΔSOFA < 0) and the SAPS 3 score at ICU admission as inde-
pendent variables in the model. These variables were selected for the model because they 
presented a p value of less than 0.20 in the univariate analysis. In this statistical model 
Δbasal, ΔCI and ΔCII, were not included since they are partial components of the BCE. 
ΔSOFA score was dichotomized between improvement (ΔSOFA < 0) and worsening 
(ΔSOFA > 0) on D3, rather than using its value in D1 and D3. The variation between BCE 
in D3 and D1 (ΔBCE) was analyzed as a continuous variable, in an exploratory analysis. 
A receiver-operating characteristic (ROC) curve was performed to evaluate the accuracy 
of ΔBCE to predict 6-month mortality. The optimal cut-off point was mathematically 
defined using the Youden index [27–31].
Statistical tests were two-tailed with significance defined as a P value less than 0.05. 
All P values were two-tailed. We used SPSS version 21.0 (SPSS, Chicago, IL, USA) and R 
4.1.0 (R Foundation for Statistical Computing) for all analyses.
Results
Clinical and epidemiological characteristics
A total of 90 patients were included in D1, but 15 deceased before D3. A total of 75 
patients were included in the D1 and D3 analysis (Fig. 1). The mean age of the patients 
was 64.8 (± 15.9) years, 42 (56% were male), and 54 (61%) with clinical ICU admission. 
The most frequent foci of sepsis were the lung (n = 41; 46%) and abdominal (n = 36; 40%) 
infections. The mean SAPS 3 score was 75.8 (± 12.9) points and the mean SOFA score 
at sepsis diagnosis was 8.5 (± 3.2) points (Table 1). At study period, 32% of the patients 
were submitted to hemodialysis and 85% to mechanical ventilation. Median arterial lac-
tate at septic shock diagnosis was 2.0 mmol/Dl (IQR 1.2–3.0), and the median volume 
of fluid resuscitation in septic shock was 44  ml/kg (IQR 30–65). Fluid balance in the 
first day of ICU admission was 2874 ml (IQR 1635–5493). Thirty-seven patients (49%) 
received hydrocortisone in the septic shock management. Maximum norepinephrine 
dose in the first day was 0.24 µg/kg/min (IQR 0.07–0.6124 µg/kg/min).
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Impact of bioenergetic and clinical variables on mortality
Overall, mitochondrial metabolic endpoints were associated with short- and long-term 
mortality. The variations (D3–D1) in the mitochondrial respiration sustained by the 
presence of endogenous intracellular substrates (ΔBasal), and the stimulated respira-
tion linked to complex II (ΔCII) were significantly decreased in non-surviving patients 
in all timepoints evaluated (Fig. 2A and C, respectively). Further, stimulated respiration 
linked to complex I (ΔCI) was decreased in 6  months non-surviving patients relative 
to surviving (Fig.  2B). Individual values for mitochondrial oxygen consumption at D1 
and D3 at basal, linked to CI and CII as well as ΔCII were associated with ICU, hospi-
tal and 6-month mortality after sepsis diagnosis (Additional file  3: Table  S1). Patients 
that deceased in the ICU presented elevated arterial lactate, C-reactive protein, capil-
lary refill time and SOFA scores at D1. These patients also had increased SOFA score at 
and D3 compared with those that survived (Table 2). BCE at D1 and D3 were reduced 
in non-surviving patients. The number of patients that improved SOFA (ΔSOFA < 0; 11 
[34%] versus 38 [88%], P < 0.001) and BCE (ΔBCE > 0; 2 [6.3%] versus 33 [77%], P < 0.001) 
was lower in nonsurvivors (Table 2). Patients that deceased during hospital admission 
had increased arterial lactate, SOFA at D1 and D3, capillary refill time and SAPS 3. BCE 
Table 1 Patient demographic and clinical variables at admission
Data are N (%), mean (SD), or median (IQR). SOFA sequential organ failure assessment, SAPS 3 simplified acute physiology 
score 3
Overall population Distribution and values
Patients, N 90
Sex
 Male 50 (55%)
 Female 40 (45%)
Age (years) 64.8 (15.9)
Clinical variables
 Surgical patients 35 (38%)
Sepsis foci
 Abdomen 36 (40%)
 Cutaneous 2 (2%)
 Blood 7 (8%)
 Urinary 4 (4%)
 Lung 41 (46%)
Capillary refill time (s) 4 (2–6)
Arterial lactate (mmol/L) 2 (1.2–3)
SvO2 (%) 70 (10.2)
PaCO2—PvCO2 (mmHg) 6.5 (3.9–10.9)
SOFA 8 (3.1)
SAPS 3 75.8 (12.8)
Clinical comorbidities
 Solid cancer 7 (8%)
 Blood cancer 7 (8%)
 HIV 2 (2%)
 Cirrhosis 7 (8%)
 Chronic kidney disease 10 (11%)
 Diabetes 25 (27%)
 Hypertension 32 (35%)
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at D1 and D3 are lower in non-surviving than surviving patients. Survivors had greater 
incidence of improvement in SOFA (ΔSOFA < 0), as well as in BCE (ΔBCE > 0) than non-
survivors (Table 2).
Patients who died within 6 months after septic shock presented elevated arterial lac-
tate levels at ICU admission and increased SAPS 3, and had the highest SOFA scores at 
D1 and D3. Survivors also had greater incidence of improvement in SOFA (ΔSOFA < 0) 
and in BCE (ΔBCE > 0) than nonsurvivors (Table  2). Remarkably, after adjusting for 
possible confounders, the 6-month mortality rate was lower in patients who had an 
improved BCE at D3 (RR 0.38, CI 95% 0.18–0.78; P < 0.001), while classic laboratory and 
clinical variables such as lactate, CRP, SOFA and SAPS 3 were not associated with sur-
vival or death (Table 3).
BCE at D1 was inversely associated with SOFA (Spearman = −  0.28; P = 0.005), but 
had no associations with arterial lactate (Spearman = − 0.2; P = 0.057) or with plasma 
C-reactive protein levels (CRP) (Spearman = 0.007; P = 0.947). Six patients (8%) devel-
oped a need for a tracheostomy during ICU admission. These patients worsened in the 
ΔBCE when compared to those who did not need a tracheostomy (− 0.085 ± 0.1 versus 
0.048 ± 0.14, respectively; P = 0.11), but without reaching statistical significance. Thirty-
six patients developed a new infection after the initial injury, and these patients had no 
statistically significant difference in their median ΔBCE when compared to those who 
did not developed reinfection (− 0.008 ± 0.23 versus 0.089 ± 0.19, respectively, P = 0.29). 
Patients who needed MV had lower values of ΔBCE when compared with those who did 
not need it, reaching statistical significance: 0.006 ± 0.14 versus 0.1 ± 0.13, respectively; 
P = 0.05. Patients who needed hemodialysis had worsening in the ΔBCE, while those 
who did not need hemodialysis had an improvement in their values (− 0.029 ± 0.1 versus 
0.07 ± 0.2; P < 0.01). Patients who improved ΔBCE (ΔBCE > 0) had a shorter ICU length 
of stay when compared with those who impaired ΔBCE (ΔBCE < 0): 6 ± 4  days versus 
9.5 ± 14  days, respectively (P = 0.02). The AUROC for ΔBCE as prognostic biomarker 
of 6-month mortality was 0.90 (95% CI 0.83–0.91, P < 0.01) (see Additional file 2: Figure 
S2). A cut-off point of − 0.002 in ΔBCE had a 100% of sensitivity and 73% of specific-
ity for the outcome (Youden’s J Index = 0.73). Distinct cut-off values of ΔBCE relative to 
sensitivity and specificity, and Youden’s J Index are shown in Table 4.
Fig. 2 Mitochondrial bioenergetic function is reduced in lymphocytes of non-surviving septic shock 
patients. Variations (day 3 minus day 1 admission) in mitochondrial oxygen consumption rates in conditions 
not stimulated by metabolic substrates (A, ΔBasal), stimulated by complex I substrates, pyruvate, malate, 
and glutamate (B, ΔCI), and stimulated by complex II substrate, succinate (C, ΔCII). Figures are presented as 
median ± IQR. *Indicates significant differences relative to surviving at P < 0.05; **P < 0.01; and ***P < 0.001
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Table 2 Univariate analysis of variables associated with ICU, hospital and 6-month mortality
Δ indicates the pairwise variation between values obtained at day 3 and day 1, mathematically represented as day 3–day 1 
for the indicated variable. Data are mean (SD), median (IQR), or n (%).CRP C-reactive protein, SOFA sequential organ failure 
assessment, ICU intensive care unit, SAPS 3 simplified acute physiology score 3, BCE biochemical coupling efficiency, COPD 
chronic obstructive pulmonary disease, CKD chronic kidney disease, CRT cardiac resynchronization therapy





















25 (58%) 21 (66%) 0.51 21 (66%) 25 (58%) 0.51 16 (64%) 30 (60%) 0.737
Sex (male) 26 (60%) 16 (50%) 0.366 18 (57%) 24 (56%) 0.97 15 (60%) 27 (54%) 0.622
Pulmonary 
sepsis
21 (51%) 12 (38%) 0.24 18 (56%) 16 (37%) 0.101 13 (52%) 21 (42%) 0.412
Solid neo-
plasia




2 (4.6%) 3 (9.4%) 0.417 1 (3.1%) 4 (9.3%) 0.386 0 (0%) 5 (10%) 0.162
Cirrhosis 1 (2.3%) 4 (13%) 0.081 1 (3.1%) 4 (9.3%) 0.386 1 (4.0%) 4 (8.0%) 0.66
COPD 7 (16%) 4 (13%) 0.647 5 (16%) 6 (14%) 0.84 3 (12.0%) 8 (16%) 0.742




11 (26%) 13 (41%) 0.167 9 (28%) 15 (35%) 0.534 7 (28%) 17 (34%) 0.6
Diabetes 11 (26%) 10 (31%) 0.589 10 (32%) 11 (26%) 0.589 9 (36%) 12 (24%) 0.275
SvO2 (%) 68.01 (6.1) 71.36 (11.6) 0.215 67.71 (9.0) 70.70 (11.1) 0.266 68.18 (9.1) 70.06 (10.9) 0.504
Lactate D1 
(mmol/L)
1.4 (1.1–2.1) 2.8 (2.0–4.0) 0.002 1.4 (1.1–1.9 2.55 (1.7–3.6 0.015 1.4 (0.9–1.6) 2.2 (1.6–3.5) 0.041
SOFA D1 7.63 (3.0) 1.0 (2.4) < 0.0001 7.25 (2.55) 9.67 (2.95) < 0.0001 7.40 (2.6) 9.26 (3.0) 0.011
SOFA D3 3 (2–5) 12.5 (7–19.5) < 0.0001 3 (1.7–5) 9 (4–16.5) < 0.0001 3 (1–4) 7.5 
(3.25–15.5)
< 0.0001
ΔSOFA < 0 38 (88%) 11 (34%) < 0.0001 28 (88%) 21 (49%) < 0.0001 22 (88%) 27 (54%) 0.004
SAPS 3 73.98 (13.2) 78.60 (12.1) 0.1 72.16 (13.1) 78.77 (12.0) 0.026 70.68 (11.2) 78.58 (12.9) 0.011









CRT D1 (s) 4 (2–4) 5.5 (3–8) 0.04 3.5 (2–4) 4 (3–7) 0.046 4 (3–4) 4 (2.25–7) 0.319
BCE D1 0.354 (0.1) 0.243 (0.1) < 0.0001 0.378 (0.1) 0.254 (0.1) < 0.0001 0.380 (0.1) 0.270 (0.1) < 0.0001
BCE D3 0.456 (0.18) 0.210 (0.1) < 0.0001 0.535 (0.1) 0.215 (0.1) < 0.0001 0.543 (0.1) 0.267 (0.2) < 0.0001
ΔBCE > 0 33 (77%) 2 (6.3%) < 0.0001 31 (97%) 4 (9.3%) < 0.0001 24 (96%) 11 (22%) < 0.0001
Table 3 Multivariate analysis of variables associated with 6-month mortality
Δ mathematically indicates the pairwise variation between values obtained at day 3 (D3) minus day 1 (D1), for the indicated 
variable. SOFA sequential organ failure assessment, SAPS 3 simplified acute physiology score 3, BCE biochemical coupling 
efficiency, CKD chronic kidney disease, RR risk ratio
Variables Multivariate analysis P
Hematological neoplasia RR 1.1 (0.37–3.26) 0.86
CKD RR 0.75 (0.22–2.48) 0.64
Lactate—D1 RR 1.01 (0.88–1.14) 0.88
ΔSOFA < 0 RR 1.01 (0.49–2.08) 0.96
SAPS 3 RR 1.01 (0.98–1.03) 0.321
ΔBCE > 0 RR 0.38 (0.18–0.78) 0.009
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Discussion
Our findings highlight a high short- and long-term mortality among septic shock 
patients. Mitochondrial metabolism in the lymphocytes of these patients provided a 
particular signature for the deterioration of clinical outcomes. Among the clinical and 
mitochondrial metabolic endpoints, ΔBCE was independently associated with long-
term mortality in our cohort.
Although SOFA is a well-validated instrument to estimate mortality risk, the addi-
tion of new and more sensitive laboratory variables to this score may benefit its predic-
tive validity. Indeed, in the “The Third International Consensus Definitions for Sepsis 
and Septic Shock (Sepsis-3)” [1], Kramer suggests the incorporation of new candidate 
biochemical markers to improve the SOFA score sensitivity. Such an approach is perti-
nent because it may provide earlier information to support clinical decisions, and thus, 
patients are more likely to achieve better clinical outcomes that reflect their prognosis 
beyond the ICU [1, 32]. In this context, our approach does not rule out the clinical rel-
evance of SOFA or other clinical scores, but proposes “a look” to a promising comple-
mentary prognostic tool. Physiologically, the mitochondria are capable of adjusting their 
metabolic energy demands and signals to protect cells from insults [7, 9, 14]. This has 
been clinically investigated in immune cells of patients with sepsis and in septic shock, 
to estimate the influence of bioenergetics on inflammatory responsiveness, severity of 
symptoms and the deterioration of health status due to organ failure [9, 33, 34]. Such 
relevance is conceptually well-illustrated by proposals that activated immune cells can 
undergo complex plasticity phenomena, which is sustained by mitochondria, “the pow-
erhouses of immunity” [6]. Accordingly, it was demonstrated in blood mononuclear cells 
that mitochondrial dysfunction and damage progress over time, along with the severity 
of symptoms, albeit strong conclusions were limited by the small number of patients [6, 
9, 34].
Here, we showed an improved metabolism from D1 to D3 (∆BCE) admission to the 
ICU which paralleled survival, implying that increments in mitochondrial bioenergetic 
function may reflect metabolic reprograming leading to improvements of the general 
health status in septic shock patients. Another study found that an early normalization 
of mitochondrial biogenesis genes expression profile accelerated sepsis recovery and 
shortened the time in the ICU [34], thus reinforcing the suggestion of clinical and func-
tional relevance in approaching mitochondrial phenotypes. Although we do not address 
gene-profile, our study conciliates the mechanistic concept that an increased biogen-
esis governs plasticity mechanisms directed to renew damaged mitochondria, and as 
Table 4 Sensitivity, specificity and Youden’s J index for measurements of ΔBCE
ΔBCE Sensitivity Specificity Youden’s 
J Index
− 0.220 100% 0% 0
− 0.111 98% 31% 0.31
− 0.002 100% 73% 0.73
0.11 70% 88% 0.58
0.219 33% 97% 0.31
0.354 3% 100% 0.03
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consequence, increase energetic efficiency. On the other hand, some intrinsic features 
support the investigation of mitochondrial bioenergetic effectors in immune cells as bio-
markers of outcomes. For instance, dysregulation of immune cells, including lympho-
cytes, are key components of inflammatory overreaction and organ failure, considered 
as hallmarks of septic shock; and as resident cells in the circulation, they survey whole 
body microenvironments, are cells easy to sample and to perform metabolic profiling in 
routine intensive care practice. The association between improved mitochondrial func-
tion with clinically relevant outcomes, such as length of stay in the ICU, the need for 
mechanical ventilation and the need for hemodialysis, reinforces this hypothesis.
The other clinically relevant spectrum of the sepsis, the compensatory anti-inflamma-
tory response syndrome (CARS), is an event that occurs in a subgroup of septic patients 
that develop profound acquired immunosuppression. Such condition may cause dif-
ficulties to efficiently eradicate the primary infection despite patients are submitted to 
standardized treatment protocols [35]. Hence, it is important to take into consideration 
that sepsis leads to a complex immune response that evolves over time, with the simul-
taneous implication of both, proinflammatory and anti-inflammatory mechanisms for 
the clinical outcomes [36]. The intensity and duration of the mentioned exacerbated 
anti-inflammatory phase seem to be closely related with the development of nosocomial 
infections. Also, an immunometabolic reprogramming in response to sepsis may rely 
on the interplay between the energy demands and capacity of lymphocyte mitochon-
dria to produce ATP [37]. However, whether or not a metabolic reprograming, here mir-
rored by BCE, exerts a significant influence in the state of immunosuppression remains 
to be explored [38]. It is known that the lymphocytes challenged by sepsis displayed an 
exhausted-like phenotype characterized by decreased functions including the capacity 
of proliferation, cytokine production and increased coinhibitory receptor expression, 
culminating in apoptotic cell death [35]. Considering that it is not completely known the 
exact extrinsic and intrinsic factors that determine the severity of lymphocytes exhaus-
tion, and likely immunosuppression, we tend to suggest decreased mitochondrial bio-
energetics as an active player. Accordingly, in physiological conditions lymphocytes are 
highly oxidative cells which implies in immunological processes highly dependent of an 
appropriate ATP support. Studies have shown a bidirectional interaction between mito-
chondria and molecular inflammatory effectors that drive cell responses to an infection. 
This crosstalk between immunogenic effectors and mitochondrial activity involves toll-
like receptors, damage-associated molecular patterns (DAMP’s), pathogen-associated 
molecular patterns (PAMP’s); and NLRP3 inflammasome activation, all driving mito-
chondrial mechanisms such as increased reactive oxygen species production, and lym-
phocyte cytokines release [39, 40].
To expand the exploratory analysis of our study, we found that patients who did not 
develop a secondary infection, who theoretically would be less susceptible to immuno-
suppression, had greater increases in BCE when compared to those who had a second-
ary infection. However, this result was not statistically significant and the sample size 
was not designed for this analysis, being any conclusions based on these observations 
merely conjectures that deserve attention in future studies.
Moreover, in cases of unresolved inflammatory-related immunosuppression activ-
ity, this condition may progress to a persistent inflammation–immunosuppression 
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and catabolism syndrome (PICS), that often evolve to a chronic critical illness state 
[41]. A hallmark of this condition is the need for a tracheostomy during the course 
of septic shock, that is associated with impairment in adaptive immunity related to 
lymphocytes [42]. In our study, patients who needed a tracheostomy had a worsening 
in BCE (data no shown), when compared with those who did not. Despite this result 
did not reach statistical significance, we believe that the small number of tracheos-
tomized patients in our sample could explain this fact.
Our study has the merits of enrolling a large number of septic shock patients in 
which the respiratory abnormalities in specific mitochondrial complexes represent 
immunometabolic targets associated with disease pathogenesis. Indeed, no previ-
ous study has integrated the activity of mitochondrial complexes CI, CII, and CV, and 
BCE in lymphocytes using two time-points, which allowed us to estimate metabolic 
reprogramming relative to the disease progression. The resulting improvement or 
worsening of the mitochondrial respiratory endpoints in the ICU highlight potential 
immunometabolic mechanistic targets, and also provide perspective regarding how 
metabolic reprogramming influences clinical outcomes. This approach outlined BCE 
as a candidate prognostic biomarker to be incorporated into clinical practice to sup-
port therapeutic management and decision-making. Although we provided promis-
ing insights regarding mitochondria bioenergetics as biomarker, this approach still 
requires advances to reach a clinical applicability. The development of ready-to-use 
assays may increase the potentialities of clinical utilization, nonetheless before pursu-
ing this goal, it is imperative to identify specific mitochondrial functions implicated 
in the response to the disease.
Our study has a number of limitations that should be further explored. It is a uni-
centric study, which may limit the external validity of the main findings. Second, it 
is a population that presented with a high risk of mortality independent of the sep-
tic shock. Even so, the mortality reported here reflects the severity measured by the 
SAPS 3 score, and it is similar to previous studies performed in Brazil and worldwide 
[43–45]. Third, we evaluated lymphocytes as a whole, albeit different types of lym-
phocytes may have specific metabolic phenotypes; however, such specificity did not 
interfere with the predictive nature of ∆BCE. Indeed, the sensitivity and specificity 
∆BCE assessed with a ROC curve further confirmed its potential prognostic value 
for 6- month mortality. As a future perspective, it is important to investigate asso-
ciations with other clinically relevant outcomes, such as clinical frailty, quality of life, 
long-term functional status, secondary immunosuppression, incidence of PICS and 
chronic organ failure after septic shock.
Conclusions
Our work highlights that impaired mitochondrial capacity to improve BCE provided 
an earlier recognition of septic shock patients in the ICU at risk of deterioration of 
health status.  On the contrary, improved BCE capacity was associated with favora-
ble clinical outcomes. Further research is needed to outline BCE as a prognostic bio-
marker to be incorporated into intensive care setting.
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